Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Where is the causal variant? On the advantage of the family design over the case-control design in genetic association studies.
The fatigue-motor performance paradox in multiple sclerosis.
Pilot study of minocycline in relapsing-remitting multiple sclerosis.
Combinatorial actions of Tgfβ and Activin ligands promote oligodendrocyte development and CNS myelination.
Therapeutic strategies of urinary disorders in MS. Practice and algorithms.
Lingo-1 Inhibited by RNA Interference Promotes Functional Recovery of Experimental Autoimmune Encephalomyelitis.
Internal jugular vein entrapment in a multiple sclerosis patient.
Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria.
[Multimodal complex treatment in multiple sclerosis : Influence on motor performance and need of care.]
The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity.
Comparison of patient-reported outcome measures in multiple sclerosis.
Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.
B-cell targeted therapeutics in clinical development.
[Compensatory mechanisms in multiple sclerosis(review)].
Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol.
Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.
Whole-Brain In-vivo Measurements of the Axonal G-Ratio in a Group of 37 Healthy Volunteers.
Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-α therapy in psoriatic arthritis.
[Non-medicinal treatments of spasticity in multiple sclerosis].
[Ginkgolide B promotes axonal growth of retina ganglion cells by anti-apoptosis in vitro].
Preliminary Investigation of Gait Initiation and Falls in Multiple Sclerosis.
An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Suicidal Behavior and Neurological Illnesses.
A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease.
Identification of a unique TGF-β-dependent molecular and functional signature in microglia.
Pages
« first
‹ previous
…
258
259
260
261
262
263
264
265
266
…
next ›
last »